Insulet drums up $85M from Cannacord Genuity
January 14, 2013 by MassDevice staff
Insulet raises $85 million in a private placement with Cannaccord Genuity.
Insulet (NSDQ:PODD) inked a private placement deal with Canaccord Genuity for $85 million worth of its common stock.
The Bedford, Mass.-based insulin management company said it plans to use the fund for marketing its OmniPod insulin pump and product development,
the company said.
Sign up to get our free newsletters delivered right to your inbox.
Similar entries
Canaccord Genuity might underwrite a 30-day option to purchase another 15% of shares offered, according to a press release.
Last month, Insulet landed an FDA nod for the next-generation OmniPod insulin pump, which is about 38% smaller and 25% lighter while maintaining the same features as existing devices.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
